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Mammalian C-type lectin receptors (CTLRS) are involved in many aspects of immune cell
regulation such as pathogen recognition, clearance of apoptotic bodies, and lymphocyte
homing. Despite a great interest in modulating CTLR recognition of carbohydrates, the
number of specific molecular probes is limited. To this end, we predicted the druggability
of a panel of 22 CTLRs using DoGSiteScorer. The computed druggability scores of most
structures were low, characterizing this family as either challenging or even undruggable.To
further explore these findings, we employed a fluorine-based nuclear magnetic resonance
screening of fragment mixtures against DC-SIGN, a receptor of pharmacological interest.
To our surprise, we found many fragment hits associated with the carbohydrate recognition
site (hit rate=13.5%). A surface plasmon resonance-based follow-up assay confirmed 18
of these fragments (47%) and equilibrium dissociation constants were determined. Encour-
aged by these findings we expanded our experimental druggability prediction to Langerin
and MCL and found medium to high hit rates as well, being 15.7 and 10.0%, respectively.
Our results highlight limitations of current in silico approaches to druggability assessment,
in particular, with regard to carbohydrate-binding proteins. In sum, our data indicate that
small molecule ligands for a larger panel of CTLRs can be developed.
Keywords: C-type lectin receptors, druggability, inhibitor, DC-SIGN, langerin, MCL, fragment screening, NMR
screening
INTRODUCTION
Glycans are present in a large diversity on cell surfaces and are
essential in many aspects of life such as embryonic development,
cell–cell communication, and regulation of the immune system
(1). In particular, our understanding of the role of glycans in
immunobiology has grown significantly during the last decades.
Three major families of secreted or membrane-bound lectins rec-
ognize carbohydrates. Complementary to other receptors of the
innate and adaptive immune system, Galectins, Siglecs, and C-
type lectins shape the response to incoming signals (2, 3). Among
many other processes, they are involved in pathogen recognition
and killing, antigen processing, and tumor progression (2, 4, 5).
Mammalian C-type lectin receptors (CTLRs) represent a large
family of lectins, which is subdivided into 17 groups based on
their phylogenetic relationships and domain structure (6). CTLRs
are present in a variety of tissues and the glycan specificity of
receptors present on cells of the innate immune system has been
studied extensively. For example, they function as homing recep-
tors on leukocytes as well as pattern recognition receptors (2, 3, 7).
A particularly well-studied pattern recognition receptor is the den-
dritic cell-specific intercellular adhesion molecules-3-grabbing
non-integrin (DC-SIGN) (8, 9). This CTLR is expressed on den-
dritic cells and macrophages and is involved in the recognition of a
large array of pathogens such as Mycobacterium tuberculosis, Leish-
mania, HCV, Ebola, and HIV (3, 10–15). It was demonstrated that
DC-SIGN promotes HIV trans-infection of T cells and has since
then drawn attention as a therapeutic target in anti-viral therapy
(10, 16, 17).
Aside from interference with pathogen recognition, leukocyte
homing has been a target for small molecule inhibition of CTLR
function. To this end, Selectins, a group of three CTLRs, have
been in the focus as anti-inflammatory drug targets since the mid-
90s (18). Only recently, the glycomimetic GMI-1070 has entered
clinical trials for the treatment of sickle cell anemia (19). Like-
wise, agonistic CTLR ligands hold promise to serve as adjuvants
for immune stimulation (20). However, despite increasing interest
in CTLRs as pharmacological targets, there is only a limited set
of small molecule agonists or antagonists available (17). Partially,
this can be attributed to the limited success of previous attempts
to find lead structures from classical drug discovery campaigns.
All CTLRs share a C-type lectin domain (CTLD) that has a
conserved fold with a characteristic double-loop stabilized by two
disulfide bridges (7, 21). This domain is often referred to as car-
bohydrate recognition domain (CRD) for those CTLRs involved
in glycan binding. Additional domains are frequently present and
in particular, heptad-repeats and collagen-like neck domains pro-
mote oligomerization, resulting in high avidity glycan binding. In
transmembrane CTLRs, CRD, and neck domain are referred to
as extracellular domain (ECD). Canonical carbohydrate recogni-
tion is mediated by a calcium ion and although there are four
Ca2+ binding sites, only the second site (Ca2+-2) is described
to be involved in coordinating glycans (21). While Ca2+-4 has
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not been associated with carbohydrate binding, positive coopera-
tive effects are observed between the other sites (22, 23). Not all
potential Ca2+ sites are occupied in every CTLD, which reflects
the fine-tuned physiological role of this interaction. For endocytic
CTLRs the pH sensitivity of the heptad-repeat neck formation
and Ca2+ coordination as well as active Ca2+ export from the
endosome are major contributors to endosomal ligand release
(23, 24). Some CTLRs bind carbohydrates in a Ca2+-independent,
non-canonical binding site with Dectin-1 being the prime exam-
ple (25). All CRDs share a carbohydrate recognition site that is
largely flat and hydrophilic. This is a consequence of glycans being
highly hydrophilic themselves (17, 26). Hence, binders are also
often hydrophilic and do not suffice the requirements for orally
available drugs (27).
Whether a protein is a suitable candidate for drug development
is of major concern during the drug discovery process. Considering
the expenses involved in the development of a pharmacologically
active small molecule, target selection has to be done carefully
(28). The modulation of a suitable drug target with a rule of five
compliant molecules should result in a therapeutic effect (29).
The term druggability, however, refers to the ability of a protein to
bind a drug-like ligand with high affinity and specificity (29–31).
Furthermore, this interaction has to result in a modulation of the
protein function. Importantly, a high druggability does not infer
the protein being a good drug target. The latter definition includes
a therapeutic effect induced by small molecule binding (32, 33).
Methods to assess the druggability of a target protein have become
good predictors prior to starting a drug discovery campaign, as
low scores are indicators for a high failure rate during later stages
of the project (30, 33).
The availability of structural information enables computa-
tional assessment of druggability. Limited resources are required
and many computational tools have been developed to deduce
druggability scores from crystallographic information (34, 35).
In a two-step process, pockets on the protein surface are first
identified and then scored (28, 32, 34, 36). Large sets of pro-
teins can be analyzed and predictions have been found to correlate
well with experimental data (31, 34, 37, 38). To the best of our
knowledge, there are only two studies on the computational drug-
gability assessments of glycan-binding proteins, both reporting
low scores (39, 40).
Experimental assessment of target druggability can be pursued
even in the absence of structural information. For this, screen-
ing of drug-like molecules in a high-throughput screening format
can be performed. Previous reports on micromolar inhibitors of
DC-SIGN resulting from a screening campaign highlight the suc-
cess of this approach (41, 42). Alternatively, a diverse library of
fragments of drug-like molecules is screened against the target.
The molecular weight of these fragments ranges between 150 and
300 Da. Estimates propose that 1000 fragments can cover a simi-
lar chemical space as 10 trillion drug-sized molecules would (33).
This in turn allows applying smaller libraries to test the drug-
gability of a candidate protein (31, 33). The low complexity of
fragments increases their likelihood of binding a receptor and con-
sequently hit rates of 5–15% are regularly observed for druggable
targets (31, 37, 43).
Small molecule fragments have low affinities with dissociation
constants in the upper micro- to lower millimolar range. Hence,
sensitive biophysical techniques are necessary to monitor this
interaction and nuclear magnetic resonance (NMR) spectroscopy
has established itself as one of the major techniques used for frag-
ment screening (31, 33, 37–39, 44, 45). In particular, hit rates
from NMR-based screenings have proven to be reliable measures
of druggability (31, 37, 44). In ligand-observed NMR, mixtures
of fragments are screened against a target and changes in NMR
observables such as chemical shift, line width, and signal intensity
upon binding allow hit identification. Notably, deconvolution of
the fragment mixtures is not necessary. The use of fluorine atoms
in drug-like fragments has proven to be instrumental (38, 46). As
fluorine is rare in biological samples, 19F NMR spectra of fragment
cocktails are not perturbed by background resonances. Moreover,
the fluorine spin is highly susceptible to changes in its chemical
environment and allows sensitive identification of hits.
To predict the druggability of human CTLRs, we compiled
a set of 22 crystal structures and analyzed it by applying com-
putational methods. We then chose DC-SIGN and conducted
experimental fragment screening to compare these findings. Low
druggability scores derived in silico did not match the moderate to
high fragment hit rates during experimental evaluation. Hence,
we expanded our screening by two additional CTLRs, namely
Langerin and MCL and discovered similarly high experimental
druggability estimates. Taken together, our results highlight the
limitations of in silico druggability prediction for CTLRs while
our fragment screening present promising grounds for inhibitor
design against this family.
MATERIALS AND METHODS
STRUCTURE-BASED MULTIPLE SEQUENCE ALIGNMENT AND
CONSENSUS STRUCTURE
The scope of structural data on human CTLRs was assessed using
the protein family (Pfam) database (accession code: PF00059)
(47). Natural killer (NK) cell lectin-like receptors were treated as
a closely related, yet physiologically distinct subfamily according
to the Pfam annotation and were not included in the analy-
sis. Furthermore, CTLRs crystallized as a domain swap dimer,
namely blood dendritic cell antigen 2 (BDCA-2) and mannose
receptor (MR), were omitted (48, 49). Murine Dectin-1 was
included in the selection as it has an unusual Ca2+-independent
carbohydrate-binding mode and no structural information of the
human ortholog is available (25). All structures considered for
analysis are listed (Table 1). If available, a structure in complex
with a carbohydrate ligand was selected. Prior to the calculations,
all structures were trimmed down to the respective CRD domain as
inferred from the Pfam domain definition. A structure-based mul-
tiple sequence alignment was performed in molecular operating
environment (MOE) (50). Pairwise root mean square deviation
(RMSD) values were determined for all pairs of Cα atoms unless
a gap was found in one of the compared sequences. Next, a phy-
logenetic analysis based on the pairwise sequence similarities was
conducted in R (51, 52). Hierarchical clustering was performed
based on the Manhattan metric and via the complete linkage cri-
terion. To complement the phylogenetic analysis, MOE was used
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to predict a consensus structure of all CRDs. During model con-
struction, up to 20 gaps and RMSD values of Cα up to 10 Å were
allowed for a single position in the multiple sequence alignment.
BINDING SITE PREDICTION AND IN SILICO DRUGGABILITY
ASSESSMENT
Initially, CTLR structures were superposed in MOE. For superpo-
sition and the subsequent druggability assessment, physiologically
relevant oligomerization states were assumed (Table 1). The EGF
domains of Selectin structures were removed. The resulting files
served as input data for binding site prediction with DoGSite (72).
The predicted binding sites were mapped on the structure and
classified into four categories following the reported nomencla-
ture of secondary structure elements and Ca2+ binding sites (21):
(i) Ca2+-2-binding sites, (ii) Ca2+-associated binding sites in long
loop, (iii) Ca2+-independent carbohydrate-binding sites, and (iv)
other binding sites. A binding site was assigned to category (i) if the
Ca2+-2 ion was part of the predicted binding site. For category (ii),
the criteria were less restrictive and all binding sites with residues
within a 6 Å radius of either Ca2+-1, 2, or 3 were included (Figure
S1 in Supplementary Material). Binding sites in category (iii) are
located in close proximity to the experimentally determined Ca2+-
independent carbohydrate-binding site. The druggability of all
binding sites was scored with DoGSiteScorer (73). Finally, cate-
gory (i), (ii), or (iii) binding sites that displayed the highest score
for a receptor were selected and this selection served to determine
a mean druggability score for the analyzed CTLRs.
CLONING
Codon optimized genes for DC-SIGN and human Langerin for
expression in E. coli were purchased from Life Technologies (Carls-
bad, CA, USA) and GenScript (Piscataway, NJ, USA), respectively.
The DC-SIGN gene included a C-terminal TEV (tobacco etch
virus) cleavage site and a Strep-tag II for affinity purification.
The ECD and CRD, ranging from amino acids 62 to 404 and
250 to 404 (Figure S3 in Supplementary Material), respectively,
were cloned into a pUC19 vector using primers including a T7
promoter and ribosomal binding site (RBS) upstream of the gene
(Table 2). Human Langerin truncated ECD, ranging from amino
acids 148 to 328, was cloned with a C-terminal TEV cleavage site
and a Strep-tag II into a pET32a expression vector (EMD Milli-
pore, Billerica, MA, USA). The MCL gene was obtained from the
DNASU Plasmid Repository (HsCD00507041, Arizona State Uni-
versity, Phoenix, AZ, USA) and the ECD was cloned into a pUC19
vector already carrying a Strep-tag II, a T7 promoter and an RBS.
For MCL ECD, amino acids ranging from 61 to 215 were used (65).
PROTEIN EXPRESSION AND PURIFICATION
All growth media or chemicals used for protein expression and
purification were purchased from Carl Roth (Karlsruhe, Ger-
many) if not stated otherwise. Proteins were expressed insolu-
ble in E. coli BL21(DE3) (New England Biolabs, Ipswich, MA,
USA) or KRX (Promega, Fitchburg, WI, USA). Precultures were
grown in 50 mL Luria–Bertani (LB) medium supplemented with
100 mg L−1 carbenicillin for DC-SIGN and MCL expression or
35 mg L−1 kanamycin for Langerin expression at 37°C in 250 mL
baffled shaking flasks at 220 rpm shaking frequency. The precul-
tures of DC-SIGN and MCL were centrifuged (3,000× g, 10 min,






ASGPR 1DV8 CRD Monomer Meier et al. (53)
CD23a 2H2T CRD Monomer Wurzburg et al. (54)
Clec1b 2C6U CRD Monomer Watson et al. (55)
Clec5a 2YHF CRD Monomer Watson et al. (56)
Clec9a 3VPP CRD Monomer Zhang et al. (57)
DC-SIGN 2XR6 CRD Monomer Unpublished
DC-SIGNR 1K9J CRD Monomer Feinberg et al. (58)
mDectin-1 2CL8 CRD Monomer Brown et al. (25)
E-Selectin 1ESL CRD–EGF Monomer Graves et al. (59)
EMBP 1H8U CRD Monomer Swaminathan et al. (60)
Langerin 3P5F CRD Monomer Feinberg et al. (61)
3KQG ECD Trimer Feinberg et al. (62)
L-Selectin 3CFW CRD–EGF Monomer Unpublished
LOX-1 1YPO ECD Dimer Park et al. (63)
MBP-C 1HUP ECD Trimer Sheriff et al. (64)
MCL 3WHD ECD Monomer Furukawa et al. (65)
Mincle 3WH3 ECD Monomer Furukawa et al. (65)
P-Selectin 1G1S CRD–EGF Monomer Somers et al. (66)
Reg3a 1UV0 CRD Monomer Abergel et al. (67)
Reg1a 1QDD CRD Monomer Gerbaud et al. (68)
SCARA4 2OX8 CRD Monomer Feinberg et al. (48)
SP-D 3IKN ECD Trimer Shrive et al. (69)
Tetranectin 1HTN CRD Monomer Nielsen et al. (70)
1TN3 ECD Trimer Kastrup et al. (71)
Table 2 | Primer sequences used for cloning.
Primer Sequence
DC-SIGN ECD F GCCGCCTCTAGAGAGTAATACGACTCACTATAGGGACT
AGAGAAAGAGGAGAAAACTAGATGGC-
CAAAGTTCCGAGCAGCATT








4°C), the supernatant was discarded, and the sediment was resus-
pended in 500 mL LB medium supplemented with 50 mg L−1
carbenicillin. The cells were afterwards cultivated at 37°C in
2.5 L baffled shaking flasks at 220 rpm shaking frequency. Pro-
tein expression was induced with 1 mM IPTG (isopropyl β-d-1-
thiogalactopyranoside) at OD600= 0.4–0.6 for additional 4 h at
37°C. The preculture of Langerin trECD was diluted directly to
OD600= 0.1 into 500 mL of LB medium supplemented with 35 mg
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L−1 kanamycin, 0.01% d-glucose, and 0.05% l-rhamnose for
autoinduction of expression. Bacteria were harvested (4,000× g,
20 min, 4°C), frozen, and resuspended in lysis buffer (50 mM Tris–
HCl, pH 7.5, 10 mM magnesium chloride, 0.1% Triton X-100,
4 mg lysozyme [Sigma-Aldrich, St. Louis, MO, USA) and 500 U
DNaseI (Applichem, Darmstadt, Germany) per gram of wet bio-
mass] and incubated on ice for 4 h. Inclusion bodies were har-
vested by centrifugation (10,000× g, 10 min, 4°C) and washed
thrice with 20 mL washing buffer (50 mM Tris–HCl, pH 8.0, 4 M
urea, 500 mM sodium chloride, 1 mM EDTA) to remove soluble
proteins.
For DC-SIGN ECD and Langerin ECD purification, the washed
inclusion bodies were resuspended and denatured in 40 mL denat-
uration buffer (6 M guanidine hydrochloride, 100 mM Tris–HCl,
pH 8.0, 1 mM DTT) and incubated at 30°C for 1 h or at 4°C over
night, following a centrifugation (42,000× g, 1 h, 4°C). The dena-
tured inclusion bodies were slowly diluted threefold with cold
binding buffer (TBS, pH 7.8 with 25 mM calcium chloride), sup-
plemented with 1 mM reduced glutathione (GSH,Applichem) and
0.1 mM oxidized glutathione (GSSG, Applichem), and afterwards
dialyzed twice against 2 L of this buffer for 24 h at 4°C. After
another 2 L dialysis against binding buffer, proteins were puri-
fied according to previously published protocols using a mannan
agarose affinity chromatography (Sigma-Aldrich) (74).
The washed inclusion bodies of DC-SIGN CRD were resus-
pended and denatured in 10 mL denaturation buffer and incu-
bated at 30°C for 1 h or at 4°C over night, following a centrifu-
gation (42,000× g, 1 h, 4°C). The solubilized inclusion bodies in
the supernatant were refolded by rapid dilution into 50 mL of
cold refolding buffer (100 mM Tris–HCl, pH 8.0, 1 M l-arginine,
150 mM sodium chloride, 120 mM sucrose) while stirring at 4°C.
After 2 days, protein solution was dialyzed against 2 L of cold
buffer W (100 mM Tris–HCl, pH 8.0, 150 mM sodium chloride,
1 mM EDTA) and aggregated protein was removed by centrifu-
gation (42,000× g, 1.5 h, 4°C). The protein was purified using a
Streptactin affinity chromatography (IBA, Goettingen, Germany)
according to the manufacturer’s instructions.
MCL refolding and purification was performed according to
Furukawa and coworkers introducing minor changes in the pro-
tocol. Briefly, purification was performed via Streptactin affinity
chromatography after dialysis against 2 L of buffer W.
FRAGMENT LIBRARY
Fragments were selected from a pool of commercially avail-
able compounds from different manufacturers (Sigma-Aldrich,
St. Louis, MO, USA; KeyOrganics, Camelford, UK; ACB Blocks,
Toronto, ON, Canada; Santa Cruz Biotechnology, Santa Cruz, CA,
USA; Vistas-MLab, Moscow, Russia; LifeChemicals, Kyiv, Ukraine;
Alfa Aesar, Ward Hill, MA, USA; TCI, Tokyo, Japan; Apollo Sci-
entific, Stockport, UK) using chemoinformatic tools as imple-
mented in MOE and KNIME (75). Only compounds with <23
non-hydrogen atoms and at least one ring were PAINS-filtered
and consecutively included in the diversity selection (76). Frag-
ment selection was based on normalized moments of inertia for
shape diversity, Tanimoto coefficient (<0.8) using MACCS fin-
gerprint for chemical diversity and scaffold diversity was ensured
following definitions given by Murcko and coworkers (77, 78).
Maximum pairwise similarities were calculated in MOE using
three-point pharmacophore-based fingerprints (GpiDAPH3) as
descriptors and Tanimoto coefficient as similarity metric. The
same descriptor was used to assess the chemical complexity of
the fragments (31).
Fragments were dissolved in d6-DMSO (Euriso-Top, Saint-
Aubin, France) to 100 mM stock solutions under a nitrogen atmos-
phere in Matrix plates (Thermo Scientific, Waltham, MA, USA)
followed by shaking at room temperature for 18 h at 140 rpm.
Fragments were stored at −20°C. Next, each fragment was dis-
solved under nitrogen atmosphere at 1 mM in 500µL 10 mM
deuterated phosphate buffer, pH 7.0, containing 50µM d4-TSP
[(3-(trimethylsilyl)-2,2′,3,3′-tetradeuteropropionic acid, Sigma-
Aldrich], 50µM TFA (trifluoroacetic acid, Sigma-Aldrich), and
0.01% sodium azide (Carl Roth). A 19F and 1H NMR spectrum of
each fragment was recorded for quality control. All NMR studies
were measured at 298 K in Norell SP5000-7 5 mm tubes (Norell,
Landisville, NJ, USA) on a Varian PremiumCOMPACT 600 MHz
spectrometer equipped with an oneNMR probe (Agilent, Santa
Clara, CA, USA) with TSP and TFA as internal references. All
spectra were analyzed in MestReNova 9.0.0 (Mestrelab Research,
Santiago de Compostela, Spain) for identity and for solubility
in D2O of at least 200µM. Substances, that did not fulfill these
quality criteria (17%), were removed from the library. Chemical
shifts were used to design 8 screening mixtures consisting of 36
compounds each. A genetic algorithm was used to solve the opti-
mization problem of mixture prediction (unpublished data). Prior
to screening, all mixtures were analyzed in 19F NMR spectra after
18–24 h incubation at room temperature to ensure stability of the
mixtures. Compounds experiencing precipitation or changes in
chemical shift were removed from the following experiments. The
quality control left 281 compounds (83%) to be prepared in mix-
tures of 100µM compound each, 100µM TFA, 150 mM sodium
chloride in 20 mM Tris–HCl, pH 7.8, in 20% D2O (Euriso-Top)
that were stored at−20°C as aliquots until used.
NMR SCREENING
All protein samples were prepared at 20µM of final concentration
in 20 mM Tris–HCl, pH 7.8, with 150 mM sodium chloride and
1 mM EDTA and mixed 1:1 with the screening mixture aliquots
resulting in a final protein and compound concentration of 10
and 50µM, respectively, in 500µL final volume. Fluorine spectra
were recorded with a spectral width of 140 ppm and a transmitter
offset at−120 ppm, acquiring 128 scans, with an acquisition time
of 0.8 and 2 s relaxation time. T2-filtered spectra were recorded
using a CPMG pulse sequence with a 180° pulse repetition rate of
50 Hz and duration of 1.0 s using same acquisition and relaxation
times (79, 80). Two CPMG spectra were recorded per mixture to
cover the full spectral width. A spectrum ranging from −50 to
−100 ppm and from −100 to −150 ppm was recorded with 96
and 256 scans, respectively. Screening was performed first in the
presence and absence of protein including 0.5 mM EDTA. Next,
calcium chloride was added to a final concentration of 10 mM
and measurements were repeated. All spectra were analyzed for
changes in peak intensity and chemical shift. As an additional qual-
ity control, frequent hitters identified during unrelated screening
campaigns were removed.
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SPR FOLLOW-UP SCREENING
All surface plasmon resonance (SPR) measurements were per-
formed on a Biacore® T100 (GE Healthcare, Chalfont St. Giles,
UK) with a flow-rate of 10µL min−1 using HBS-P buffer
[10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid), pH 7.6, 150 mM sodium chloride, 0.05% Tween-20] at
298 K. DC-SIGN ECD was immobilized on a CM7 Series S sensor
chip in a density of 3317 RU using 0.2 M EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, Sigma-Aldrich) and 0.05 M
NHS (N -hydroxysuccinimide, Merck, Hohenbrunn, Germany) as
coupling reagents. The activated surface was saturated with 1 M
ethanolamine (Sigma-Aldrich), pH 8.5, after immobilization. The
reference flow cell was treated in the same manner without immo-
bilizing protein. Prior to measurements, the solubility of each
compound in SPR buffer was determined by recording absorption
spectra at different concentrations between 400 and 800 nm in
clear 96-well plates (Nalge Nunc International, Penfield, NY, USA)
in a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale,
CA, USA). During SPR measurements, fragments were injected
for 30 s following a dissociation time of 120 s at 10µL min−1 flow-
rate omitting regeneration as fast off-rates were observed for all
ligands. To estimate the apparent affinity of a compound, at least
three dilutions between 0.1 and 1 mM depending on the solubility
were run in triplicates, blanking the data against a corresponding
DMSO control. A positive control was included during screening
to ensure stability of the sensorgrams. A 1:1 binding model was
applied for data fitting:
RU = RUmax [L]
KD, app+[L]
(1)
with the fragment concentration [L], the measured relative
response units RU, the apparent dissociation constant K D,app, and
the maximal relative response units RUmax using Origin8.6Gpro
(OriginLab, Northampton, MA, USA). The maximal relative
response units were estimated using:




with the immobilization level of protein RUimmobilized, the mol-
ecular weight of the compound and protein MWcompound and
MWprotein, respectively, and the remaining activity of the protein
on the chip A. The latter was determined to be 0.6 using 4 as posi-
tive control (Figure S4 in Supplementary Material). The apparent
affinity constant for each compound was determined under two
conditions, either in the presence of 0.5 mM EDTA or 2 mM cal-
cium chloride included in the running and sample buffer. Ligand
efficiencies (LE) were calculated applying






using the apparent dissociation constant K D,app, the temperature
T, the gas constant R, and the number of non-hydrogen atoms
HA (81).
RESULTS
STRUCTURE-BASED SEQUENCE ALIGNMENT IDENTIFIES CANONICAL
CARBOHYDRATE-BINDING SITES
A comparative framework between the CTLRs served as the start-
ing point of our druggability prediction. To this end, a structure-
based sequence alignment was performed for 22 CRDs (Figure S3
in Supplementary Material). With an average of 41%, the global
sequence similarity within the set of receptors is low. It spans
a range from 26 to 86% (Figure 1A). A phylogenetic analysis
based on this alignment yields a dendrogram that resembles the
canonical classifications of CTLRs, in particular with respect to the
correct assignment of members of the groups II, III, IV, V, and VII
(1). Collectin-12 deviates from this classification, as it is part of
the group II cluster. Moreover, Tetranectin and eosinophil major
basic protein (EMBP) are the only representatives of group IX and
XII used in this study. Both display elevated distances to other
branches. EMBP and Tetranectin as well as Clec9a, Lox-1, Clec1b,
and Reg1a have been reported to interact with non-carbohydrate
ligands and all of these CTLRs were assigned to cluster B. Strikingly,
CRDs known to recognize carbohydrates via the Ca2+-2-binding
site are exclusively present in cluster A (Figure 1A).
CONSENSUS STRUCTURE PREDICTION REVEALS ELEVATED
STRUCTURAL VARIABILITY IN THE LONG LOOP
Contrasting the low global sequence similarity, the overall struc-
ture of the CTLD is highly conserved. RMSD values of Cα atoms
obtained from the structure-based multiple sequence alignment
are uniformly low and do not exceed 3.2 Å (Figure 1A). To visu-
alize the conservation of the domain architecture, we calculated
a consensus structure (Figure 1B). While the core of the CTLD
displays only minor deviations, a higher level of structural vari-
ability characterizes the two loop regions. The long loop is of
particular interest as it harbors the Ca2+-1, -2, and -3 sites and
thus plays a fundamental role in Ca2+-dependent carbohydrate
recognition (21).
COMPUTATIONAL ANALYSIS PREDICTS LOW DRUGGABILITY FOR THE
MAJORITY OF CTLRs
The initial identification of binding sites with DoGSite yielded
between three and nine sites for CRDs and 9–19 for ECDs. Next,
DoGSiteScorer was applied to calculate druggability scores. In the
scoring scheme of this program, scores over 0.5 are indicative of a
druggable binding site (73). At least one site that meets this crite-
rion is found for the majority of the analyzed CTLRs (Figure 2A).
However, targeting these sites with drug-like molecules will not
necessarily exert an effect on the physiological function of the
respective CTLR.
We propose that binding sites in proximity to Ca2+ ions located
in the long loop region are relevant to carbohydrate recognition.
Therefore, we assumed that small molecule-binding to these sites
potentially modulates CTLR function. To this end, binding sites
were assigned to four categories: (i) Ca2+-2-dependent, (ii) Ca2+-
associated binding sites, (iii) Ca2+-independent carbohydrate-
binding sites, and (iv) other binding sites (Figure 2A). Ca2+-
associated binding sites (i, ii) were identified by DoGSite for all
CTLRs coordinating a Ca2+-2 ion except for Mincle and the
Langerin trimer. Experimentally determined Ca2+-independent
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FIGURE 1 | Sequence alignment and consensus structure of CTLRs.
(A) The dendrogram depicts the hierarchical clustering of CRDs based on a
structure-based multiple sequence alignment. The two major branches are
termed cluster A and B. Pairwise sequence similarities and RMSDs of Cα
atoms are shown in matrix format. (B) Key structural features of the CTLD
fold are mapped on the predicted consensus structures (top). The peptide
backbone is displayed as a continuous line and colored according to RMSD of
Cα atoms. The CRD of DC-SIGN (PDB code: 2XR6) is shown for comparison
(bottom). The ribbon representation is colored according to secondary
structure elements (red: α-helices; yellow: β-strands; blue: loop regions).
carbohydrate-binding sites (iii) were identified for DC-SIGN,
DC-SIGNR, and Reg3a (58, 82). The existence of a single drug-
gable site is sufficient to render a target druggable. Accordingly,
for each CTLR, sites assigned to categories (i) and (ii) display-
ing the highest score were selected for statistical analysis and
a mean druggability score of 0.47 was calculated (Figure 2B).
This classifies CTLRs as “difficult” or even “undruggable” targets
(73). Notably, individual receptors such as SP-D and Collectin-12
possess favorable pockets in the long loop region. Other tar-
gets such as E-Selectin display druggability values well below
the mean.
FRAGMENT SCREENING REVEALS HIGH HIT RATES AGAINST DC-SIGN,
LANGERIN, AND MCL
The existence of pockets on the surface of a receptor that are
suitable to accommodate drug-like ligands can be assessed exper-
imentally using fragment screening. The resulting hit rate serves
as a predictor for druggability. Therefore, we composed a chem-
ical library of fragments to be used in a homogeneous, label-
free NMR-based screening assay. All fragments carry a fluorine
atom, which allows for 19F NMR spectroscopy-based assessment
of fragment binding. After quality control, 281 fragments were
available for screening in 8 mixtures of maximum 36 fragments.
The fragment library displays high shape and chemical diversity
(Figures 3A,B).
DC-SIGN CRD and ECD were screened against the fragment
library using 19F and T2-filtered 19F NMR spectra. Fragment bind-
ing to DC-SIGN was observed monitoring changes in chemical
shift, line broadening, and T2 relaxation. Moreover, three spec-
tra were recorded per fragment mixture. First, a spectrum was
recorded in the absence of protein to exclude false positives such
as Ca2+ chelators. The second spectrum was acquired in the pres-
ence of 10µM protein to monitor fragment binding. Finally, Ca2+
was added in excess to the protein-fragment mixture, hypothesiz-
ing that metal binding to DC-SIGN modulates interaction of those
fragments that are good candidates for inhibition of carbohydrate
recognition (vide supra). Hits for DC-SIGN CRD and ECD were
combined and frequent hitters were removed. Consequently, we
identified 38 hits (13.5%) from mixtures binding to DC-SIGN in
a Ca2+-dependent manner (Figure 3C). Out of these hits, 16 were
found in both screenings and 21 hits were identified only during
the CRD screening. Only one fragment was found while the ECD
was used for screening.
To further validate these hits, SPR spectroscopy was employed
as an orthogonal biophysical assay. This method not only detects
binding of small molecules to macromolecules, but also allows
for the determination of equilibrium dissociation constants.
DC-SIGN ECD was immobilized on the chip surface and two
experimental setups were utilized to differentiate Ca2+-mediated
fragment binding from Ca2+-fragment competition. Fragments
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FIGURE 2 | Computational druggability prediction of CTLRs.
(A) A comprehensive account of all binding sites predicted by DoGSite is
given. CTLRs were grouped according to the structure-based multiple
sequence alignment. A druggability score of <0.5 is indicative of an
undruggable binding site (dotted line). Binding sites are colored according to
the corresponding category (red: Ca2+-2-binding sites (i), green:
Ca2+-associated binding sites in long loop region (ii), blue: previously reported
Ca2+-independent carbohydrate-binding sites (iii), gray: other binding sites).
(B) A boxplot of the highest druggability scores of categories (i) to (iii) of each
CTLR is shown. Tukey-style representation was chosen.
were injected either in the presence of 0.5 mM EDTA or 2 mM
calcium chloride (Figure 3D), confirming a 1:1 binding model
for 18 fragments (47%). Five fragments (13%) bound with a
higher stoichiometry, 3 experienced no change in response in
presence or absence of Ca2+ (8%), and 12 fragments (32%) did
not give rise to detectable signals. The highest affinities mea-
sured were in the upper micromolar to lower millimolar range
(0.6 mM<K D,app > 1.3 mM). Of the 18 fragments confirmed by
SPR, 9 showed increase in affinity upon Ca2+ addition and 9
displayed competitive behavior. Moreover, fragments similar to
substructures of an already published submicromolar DC-SIGN
inhibitor were identified (41, 42) (Figure 4). While fragments 1
and 2 bound competitive with the polysaccharide mannan in a
19F NMR competition assay, fragment 3 showed no such behavior
upon addition of the natural carbohydrate ligand of DC-SIGN
(data not shown).
In light of our computational analysis, we were surprised to
find such a high fragment hit rate for DC-SIGN, and decided to
expand our 19F NMR-based druggability prediction against the
ECDs of two further CTLRs. We decided to screen our fragment
library against Langerin being sufficiently distant to DC-SIGN
in our structural sequence alignment (Figure 1A). To compare
these findings to a CTLR more closely related to Langerin, we also
included MCL in our analysis. Both proteins were expressed in
E. coli and screened following the same protocol as for DC-SIGN.
Again, Ca2+ was utilized as a competitor (Figures S5A,B in Supple-
mentary Material) and several hits associated with Ca2+ binding
were identified (Table 3). The pairwise overlap between the three
CTLRs was low and none of the fragment hits bound to all CTLRs
(Figure S5C in Supplementary Material).
DISCUSSION
In this report, we assessed the potential of human CTLRs to be tar-
geted with drug-like molecules. Therefore, we explored the ability
of a set of CTLRs to accommodate inhibitors to modulate the
receptor–carbohydrate interaction. This druggability prediction is
an important part of the decision on whether a drug discovery
campaign should be pursued (28–30). Despite a large body of
recent research highlighting the importance of CTLRs in immune
cell regulation, pathogen uptake, and as targets for adjuvants, only
a few drug-like molecules have been developed for the CTLR family
(2, 16, 17, 20). Herein, we aimed to rationalize why these receptors
are considered challenging targets.
To start our investigations, CTLR druggability was predicted
by computational methods. No data focusing on CTLRs are avail-
able and more general reports on glycan-binding proteins pre-
sented low druggability scores (39, 40). Unfortunately, the exact
structures were either not disclosed or highly redundant and no
CTLR was explicitly included. We assembled a set of 21 human
CTLRs, and the murine Dectin-1. The latter was included as a
reference as it is a well-studied CTLR and harbors a potential non-
canonical, calcium-independent carbohydrate recognition site.
The druggability prediction was performed using DoGSiteScorer,
recently released software to predict the druggability of pro-
tein targets based on structural and physicochemical properties
(73). Here, potential pockets on the protein surface were iden-
tified first, and then scored according to their physicochemical
properties. Major determinants of druggability are depth, vol-
ume, and amino acid composition of the pocket (28, 32, 34, 36,
73). Generally, highly hydrophilic binding sites are considered
undruggable (36).
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FIGURE 3 | Fragment library and screening against DC-SIGN.
(A) Molecular shape distribution of the 281 fluorinated fragments was
assessed using normalized moments of inertia plots of the fragment library
(top) and molecules from the ZINC database fragment set (bottom). (B) The
diversity of the library is displayed for a selection of molecular descriptors.
Histograms of the maximum pairwise similarity, number of non-hydrogen
atoms, number of rotatable bonds, molecular complexity, and number of
hydrogen bond donors/acceptors are shown. (C) Examples from the
19F NMR screen using T2-filtered spectra (T =1.0 s, νCPMG =50 Hz) showing
compounds that do not bind (1), bind Ca2+-dependently (2), are competed by
Ca2+ (3) and are binding at another binding site (4). (D) Sensorgrams for
three examples from the SPR follow-up are shown. DC-SIGN ECD was
immobilized on a CM7 chip. A one-site-binding model was used for fitting
the data. This exemplifies compounds that experience increased (top),
decreased (middle), or no alteration of affinity (bottom) in the presence of
Ca2+. Data were extracted from regions of the sensorgram not perturbed by
injection peaks. SPR sensorgrams are representatives of three independent
measurements.
Between three and nine binding sites were identified for CRDs,
which is in accordance with values reported for other protein fam-
ilies (32). For Langerin, MBP-C, and Tetranectin, data on the
homo-trimeric form were available. Here, the algorithm identi-
fied more potential sites, which is not surprising due to the larger
surface area and symmetry of the assemblies (Figure 2A). Yet, tar-
geting this initial set of binding sites does not necessarily interfere
with carbohydrate recognition. Therefore, we categorized pock-
ets according to their potential to modulate glycan binding. We
argue that a druggable pocket located in close proximity of the
long loop renders it a potential binding site for an inhibitor. The
loop exhibits considerable movement in the absence of calcium as
observed for other CRDs (65, 67, 83, 84) and adjacent sites have
been proposed to communicate with the primary carbohydrate
recognition site (22, 23). Four categories of sites were defined out
of which only two, namely categories (i) and (ii), are either directly
or indirectly associated with calcium ion binding.
The success-rate of detecting the canonical Ca2+-2 site (i) was
low. Only 4 out of the 14 structures known to harbor such a site
were identified (Figure 2A). This low number reflects a limita-
tion of the employed pocket prediction, potentially due to shallow
architecture of the Ca2+-2 sites. The low druggability score of
the successfully identified Ca2+-2 sites corroborates this finding.
Overall, these findings suggest that identification of carbohydrate
recognition sites with computational algorithms such as DoGSite
is challenging (vide infra).
Moreover, we analyzed a larger panel of sites associated with
either the Ca2+-1, -2, or -3 site, summarized in category (ii)
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FIGURE 4 |Three fragment hits against DC-SIGN. Fragments 1, 2, and 3
were identified during the primary 19F NMR screening and later confirmed
in an SPR follow-up assay. These fragments are similar to substructures of a
previously published micromolar DC-SIGN inhibitor 4 (41). Affinities
measured in the presence of EDTA and Ca2+ are highlighted in black and
red, respectively. No binding (n.b.) was detected in presence of EDTA for
fragments 1 and 3. SPR measurements were run in triplicates for each
condition.
Table 3 | Hit rates for three C-type lectin receptors from 19F NMR
screening against a library of 281 compounds and hits confirmed by
SPR for DC-SIGN.
C-type lectin receptor Ca2+-associated hits Validated hits by SPR
DC-SIGN 38 (13.5%) 18 (6.4%)
Langerin 44 (15.7%)
MCL 28 (10.0%)
(Figure 2A). The criteria of this category were less stringent and
based on an extended definition of sites potentially interfering
with carbohydrate binding. Again, druggable sites were sparse.
Collectin-12 and SP-D, both members of the Collectin group
(CTLR group III), represent notable exceptions. Furthermore, our
data on Langerin, for which monomer and trimer were analyzed
side by side, highlight that subtle changes in the long loop region
upon oligomerization abrogate the recognition of these sites by
DoGSite (62).
Low scores for category (ii) sites are also found for members
of cluster B of the sequence alignment. This cluster exclusively
contains CTLRs not known to bind carbohydrates with their
Ca2+-2 site (Figure 2A). The Ca2+-independent carbohydrate-
binding sites of category (iii) found for Reg3a (group VII) is
located in other regions of the CRD fold and has druggability
scores of 0.56, predicting this CTLR to be challenging (82). Over-
all, only a few members of the CTLR family were predicted to be
druggable (Figure 2B), which is in line with previous reports on
glycan-binding proteins (39, 40).
To substantiate the computational studies, a 19F NMR-based
fragment screening against one of the analyzed CTLRs was con-
ducted. We chose DC-SIGN because as a viral uptake receptor
it is of pharmacological interest and has been targeted in a
high-throughput screening (41). While the successful HTS was
already an indicator of DC-SIGN being amendable to fragment
binding, the low druggability assessment by our computational
analysis predicted a low hit rate of fragments interfering with any
of the three DC-SIGN calcium sites. To our surprise, a high hit
rate of 13.5% of the fragments from our library bound to DC-
SIGN in Ca2+-associated sites during the NMR screening. The
follow-up screening via SPR validated 18 (47%) of these frag-
ments, a value not unusual for these two assay systems (85). Hits
that were not validated by the SPR screening were either super-
stoichiometric binders (13%), not competitive with Ca2+ (8%),
or had affinities below the detection limit of the SPR assay. The
latter can be attributed to the high sensitivity of 19F NMR as
a primary screen (38). Together, NMR and SPR result in a hit
rate of 6.4%, which is in the expected range for fragment-based
screenings and does not suggest a low likelihood to bind drug-like
molecules (31, 37, 43, 86).
We performed the primary NMR screen against the CRD and
the tetrameric ECD of DC-SIGN. Notably, only one fragment was
uniquely identified during the screening of the ECD compared
to 21 in the CRD screening. Conversely, many fragments bind-
ing to the ECD were later discovered to be false positives, such as
frequent hitters from unrelated screening campaigns against non-
CTLR targets. Hence, we conclude that screening for inhibitors
has a lower false positive rate in absence of the neck region of
DC-SIGN.
Another indicator for the validity of our screen to discover
fragments inhibiting carbohydrate binding to DC-SIGN was the
identification of the three fragments 1, 2, and 3. These hits are
similar to substructures of the previously reported micromolar
DC-SIGN inhibitor 4 (Figure 4) (41). In this respect, four has
been shown to compete with carbohydrate binding and antago-
nized the DC-SIGN-mediated cell adhesion and particle uptake
(41, 42). Direct competition between four and the three frag-
ments was hampered by direct interaction of the fragments with
four in absence of DC-SIGN (data not shown). Thus, man-
nan was employed to compete with fragments 1–3 and resulted
in reproducible competition with fragments 1 and 2 (data not
shown). Although, fragment 3 did not experience competition
with the natural ligand, it can be speculated that it is associ-
ated with the binding site, as recognition was detected in SPR
only in presence of Ca2+ (Figure 4). Moreover, other fragment
hits showed even higher LE ranging from 0.30 to 0.37, which is
a good starting point for further fragment evolution. A subse-
quent expansion of our 19F NMR-based screening to Langerin
and MCL, also revealed similarly high hit rates (Table 3). Follow-
ing up on these initial hits is subject of current research in the
laboratory.
These encouraging experimental results are in contrast to our
computational predictions. We attribute this conflict to the lim-
itations of the DoGSiteScorer algorithm, which on the one hand
is not parameterized for carbohydrate or metal binding sites (72)
and on the other does not account for protein flexibility. Currently,
there is no single software for druggability prediction available that
is able to overcome these limitations.
Throughout the experimental evaluation, we employed com-
petition with calcium ions as an indicator for the inhibition of
carbohydrate recognition. We assumed the existence of allosteric
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sites originating from the flexibility of the long loop and coop-
erativity between the adjacent sites as previously described for
other CTLRs (22, 23, 65, 67, 83, 84). In this context, it should be
noted that accounting for conformational dynamics is recognized
as a particular challenge for the development of improved
algorithms (34).
To summarize, we report high in silico druggability scores for
group III and V CTLRs as well as high experimental hit rates from
fragment screenings against group II CTLRs. These data stand
alongside with a successful drug design campaign that has already
been launched against group IV CTLRs (19). Hence, we conclude
that our data, while highlighting the limitations of current com-
putational methods, support the assessment of CTLRs as suitable
targets for drug-like molecules.
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